ERBB2 and gastric cancer: Targeted therapies have transformed the treatment landscape for gastric cancer, with HER2 inhibitors (e.g., trastuzumab) [4] and immune checkpoint inhibitors (e.g., pembrolizumab) representing major advancements [5].